Revenue
34 thousand
2022 Q4 ·
Fundies. English
CytoDyn, Inc.
EDGAR150 filing records in this dataset, filed from 2002-10-15 to 2026-10-19. Reported financial figures are available; chart coverage varies by period.
Latest quarter
Operating margin
-232,494.12%
2022 Q4 · %
Exact inputs and evidence
- Cash and cash equivalents
- 16.4 million USD Source
Exact value
16359000 USD
- Long-term debt including current maturities
- 35.8 million USD Source
Exact value
35809000 USD
- Shares outstanding
- 1.45 billion shares Source
Exact value
1454354000 shares
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-10-19.
Financial data available through: 2026-05-31.
Coverage by financial measure
- Revenue: Multiple units; comparison withheld· newest 2023-05-31
- Operating income: 7 of 11 periods available· newest 2026-05-31
- Net income: 7 of 11 periods available· newest 2026-05-31
- Operating cash flow: 7 of 11 periods available· newest 2026-05-31
- Capital expenditure: Multiple units; comparison withheld· newest 2021-05-31
- Total assets: 7 of 11 periods available· newest 2026-05-31
- Total liabilities: 7 of 11 periods available· newest 2026-05-31
- Current assets: 7 of 11 periods available· newest 2026-05-31
- Current liabilities: 7 of 11 periods available· newest 2026-05-31
- Cash and cash equivalents: 7 of 11 periods available· newest 2026-05-31
- Long-term debt including current maturities: 3 of 11 periods available· newest 2026-05-31
- Shares outstanding: 7 of 11 periods available· newest 2026-05-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Net income
-1,240.2%Prior period
USD 3.75 million
–
Current period
−USD 42.7 million
–
Exact inputs and evidence
-42699000 − 3745000 = -46444000 USD
3745000 USD · 2024-06-01 – 2025-05-31
Inspect prior input Prior source-42699000 USD · 2025-06-01 – 2026-05-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 8.49 millionPrior period
−USD 8.77 million
–
Current period
−USD 17.25 million
–
Exact inputs and evidence
-17252000 − -8765000 = -8487000 USD
-8765000 USD · 2024-06-01 – 2025-05-31
Inspect prior input Prior source-17252000 USD · 2025-06-01 – 2026-05-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Revenue, Capital expenditure.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
Revenue is not reported for this company, so its costs cannot be shown as a share of it.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Revenue growth
Change in revenue from the same financial period one year earlier.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Not enough comparable data to show this history.
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|
Operating cash flow
Cash generated by the company’s normal business operations.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Current assets to current liabilities
Current assets divided by current liabilities.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2016 2015-06-01 – 2016-05-31 | −USD 25.7 million Exact valueExact value: -25703612 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 24.81 million Exact valueExact value: -24810651 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2017 2016-06-01 – 2017-05-31 | −USD 25.76 million Exact valueExact value: -25763801 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 26.73 million Exact valueExact value: -26732468 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2018 2017-06-01 – 2018-05-31 | −USD 50.15 million Exact valueExact value: -50149681 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 29.9 million Exact valueExact value: -29897971 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2019 2018-06-01 – 2019-05-31 | −USD 56.19 million Exact valueExact value: -56186660 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 50.47 million Exact valueExact value: -50466164 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2020 2019-06-01 – 2020-05-31 | −USD 124.4 million Exact valueExact value: -124403402 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 68.8 million Exact valueExact value: -68803615 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2025 2024-06-01 – 2025-05-31 | USD 3.75 million Exact valueExact value: 3745000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 8.77 million Exact valueExact value: -8765000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2026 2025-06-01 – 2026-05-31 | −USD 42.7 million Exact valueExact value: -42699000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 17.25 million Exact valueExact value: -17252000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
150 filings · 5,381 latest values · 5,381 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001175680, 1175680, CYDY, edgar:1175680
Also known as CYTODYN INC, CYTODYN INC., CYTODYN INC., CytoDyn Inc., CytoDyn, Inc., CytoDyn Inc., REXRAY CORP